Results 41 to 50 of about 18,181 (226)

Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals

open access: yesNature Communications, 2018
The specific glycosylation patterns of biological drugs often impact the efficacy and safety of the therapeutic product. Here the authors describe a native mass spectrometry approach that allows the resolution of highly complex glycosylation patterns on ...
Therese Wohlschlager   +7 more
doaj   +1 more source

Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions

open access: yesAngewandte Chemie International Edition, EarlyView.
Multivalent, ligand‐directed molecular beacons enable fluorescence turn‐on detection of cell‐surface receptors in living cells. The probes strongly engage closely spaced membrane receptors and exhibit conformation‐dependent fluorescence enhancement at the cell surface, enabling wash‐free receptor imaging, inhibitor screening, and functional evaluation ...
Noa Oppenheimer‐Low   +11 more
wiley   +1 more source

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia

open access: yesNeurology and Therapy
Introduction TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension suitable for subcutaneous administration from a prefilled syringe.
Itay Perlstein   +9 more
doaj   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian   +8 more
wiley   +1 more source

Switching from one infliximab biosimilar ({CT}-P13) to another infliximab biosimilar ({SB}2) in patients with chronic plaque psoriasis

open access: yes, 2020
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar ...
C. Virga   +6 more
core   +1 more source

Biosimilars in oncology

open access: yesESMO Open, 2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire   +3 more sources

Biosimilars in rheumatology

open access: yesPharmacological Research, 2019
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C.   +2 more
openaire   +3 more sources

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

open access: yes, 2021
International audienceOver time, clinicians have become increasingly comfortable embracing the prescription of biosimilars-highly similar versions of innovator or reference biological agents-for their patients with inflammatory diseases.
Mueller, Markus   +7 more
core   +1 more source

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

open access: yesFrontiers in Pharmacology, 2017
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with ...
Tim A. Kanters   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy